IMPORTANCE Amyotrophic lateral sclerosis (ALS) has an immune component, but previous human studies have not examined immune changes over time.
; often the same cell type can play a positive or negative role depending on the stage of disease. 11, 12 This process likely explains why previous clinical attempts to use immune suppression in patients with ALS had no positive effect 13, 14 or exacerbated disease. 15, 16 Previous studies 9, [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] demonstrated that peripheral immune changes occur in patients with ALS. Moreover, disease progression in murine models of ALS can be modulated by manipulating individual immune cell populations.
27-30
This modulation makes blood-borne leukocytes attractive as biomarkers and targets for ALS therapies because such strategies would be less invasive than those targeting the CNS. We hypothesize that specific leukocyte populations or myeloid subpopulations accelerate the rate of ALS progression. In the present study, cellular populations and myeloid surface marker expression from participants with ALS were obtained longitudinally, and multivariate regression analysis was used to correlate changes in immune cell populations with changes in disease scores.
Methods

Study Population
Participants with ALS who met a diagnosis of possible, probable laboratory-supported, probable, or definite ALS based on revised El Escorial criteria 31 were recruited from the ALS Clinic of the University of Michigan, Ann Arbor, from June 18, 2014, through May 26, 2016. Disease progression, measured using the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R; range, 0-48, with lower scores indicating more advanced disease), was abstracted from medical records and collected prospectively. Control participants, recruited through the university, were excluded if they had a family history of ALS, previous diagnosis of a neurodegenerative disorder, chronic inflammatory disease, collagen vascular disease, use of immunomodulatory medication, or any fever or sickness at the time of blood sample obtainment. The study was approved by the institutional review board of the University of Michigan; all participants provided oral and written informed consent.
Blood Samples
Blood samples were collected by peripheral venipuncture into a sodium heparin tube (BD Vacutainer; BD Biosciences), placed at 4°C, and processed within 2 hours of collection. A 1-mL aliquot of whole blood was lysed with red blood celllysing buffer (0.8% ammonium chloride, 0.098% potassium hydrogen carbonate, 0.1mM EDTA, and 13.8mM Hepes), and washed twice with flow buffer (phosphate-buffered saline, 4% fetal bovine solution, and 0.1% sodium azide). An aliquot was counted using a hemocytometer (Hausser Scientific).
Flow Cytometry
Cells were incubated with blocking solution (TruStain FcX; Biolegend). A cocktail of titrated, monoclonal, fluorochromelabeled antibodies (eTable 1 in the Supplement) was added to each well and incubated in the dark at 4°C for 30 minutes. Cells were washed with flow buffer, spun down, and resuspended in stabilizing fixative (BD Biosciences). Phenotyping was performed on a cytometer (BD FACS Canto II; BD Biosciences). Compensation for each color used cells stained with a single fluorochrome-labeled antibody. Isotype control gates were set at no greater than 1.0%.
Leukocyte Population Gating
Myeloid populations were identified using CD11b, CD14, and CD16 (eFigure 1 in the Supplement). Neutrophil (CD16 high ) and eosinophil (CD16 low ) gating was confirmed with CD15 and CCR3 expression, respectively.
32 Lymphocyte and lymphoid populations were identified using antibodies for CD3, CD4, CD8, CD56, and CD16 (eFigure 2 in the Supplement).
Myeloid Surface Marker Expression
Surface marker expression within the 2 CD14 + monocyte groups was calculated using median fluorescence intensity (MFI). For each myeloid population, the MFI of each surface marker was calculated as well as that of the corresponding IgG isotype control. Surface marker MFI expression was divided by the isotype MFI expression, and data were assessed based on the MFI fold increase. CD14 − myeloid cell subpopulations were identified based on positive and negative surface marker expression (eFigure 3 in the Supplement). Expression and function are outlined in eTable 2 in the Supplement.
Statistical Analysis
To compare controls and participants with ALS, data for each participant with ALS were pooled from multiple visits to generate a single value for each immune metric. This procedure
Key Points
Question Are changes in the number or activation of specific immune cells in peripheral blood correlated with rapid progression of amyotrophic lateral sclerosis?
Finding 
Multivariate Regression
Correlation between cellular population changes and disease progression was assessed for participants visiting initially within the first 3 years after disease onset. The gap time between disease onset and the first visit among the 119 participants with ALS varied significantly ( Table 1) ; thus, restricting the analysis to participants whose first visit was within 3 years of disease onset reduced patient heterogeneity in terms of disease progression. A 2-step process assessed the association between cellular population changes and disease progression. First, linear regression models of the cell population counts and ALSFRS-R scores on time were fitted to estimate the participant-specific rate of change in these variables. Median fluorescence intensity expression and CD14 − cell population counts were transformed by taking the logarithm or the square root to improve normality. Second, a multiple linear regression model was fitted to assess whether the rate of change in cellular population counts was associated with disease progression after controlling for potential confounders (ie, baseline biomarker value, age at onset, and sex). A separate model was fitted for each biomarker to assess its association with disease progression. Analyses were performed using R software (https://www.r-project.org/).
Results
Population Demographics
The Table 2) . Next, the number of immune cells in the peripheral blood samples from each participant was plotted over time (eFigure4AintheSupplement) or in association with the ALSFRS-R score (eFigure 4B in the Supplement) for participants who had enrolled in the study within 3 years of disease onset. Consistent with previous reports, leukocyte numbers were highly variable over time, even within the same participant.
35 However, we found increasing total numbers of leukocytes, neutrophils, and NK cells; conversely, the total number of CD4 cells appeared to decrease during the first years of disease progression ( Table 3) . We also observed large but transient increases in CD11b + CD14 − CD16 − cell count.
To determine whether changes in any cell populations might play a role in disease progression, we created a multivariate linear model of regression using data from participants whose first visit to the clinic occurred within 3 years of disease onset. Changes in the immune cell population counts were correlated with changes in ALSFRS-R score between time points. We found a significant correlation between a decrease in ALSFRS-R score and changes in the total number of immune cells (−3.68 [95% CI, −5.45 to −1.92] per 6.34 × 10 4 /mL [ SD ,47 . 91×10 4 /mL] increase per year; P < .001) ( Table 3) .
Changes in the number of neutrophils were also significantly correlated with a decrease in ALSFRS-R score (−4.37 [95% CI, −6.60 to −2.14] per 11.47 × 10 4 / mL[ SD ,58 . 04×10 4 /mL] increase per year; P < .001). On average, the total numbers of leukocytes and neutrophils increased over time, indicating that early increases in total leukocyte and neutrophil numbers are correlated with disease progression. We also observed a correlation between changes in ALSFRS-R score and changes in the number of CD4 P < .001); however, CD4 T-cell levels decreased over time, and the rate of decrease was correlated with a drop in ALSFRS-R score. Other cell types showed no significant correlation between early population changes and ALSFRS-R score. Although NK cell changes were not directly correlated with changes in ALSFRS-R scores, these cell levels increased by a mean of 80 000/mL of blood per year in participants with ALS in the initial stages of disease (a 60% yearly increase vs controls). 
Discussion
This study examined long-term changes in the peripheral immune system of participants with ALS and correlated these changes with disease progression. Leukocytes were isolated from the peripheral blood samples of participants with ALS and healthy controls; the total number of numerous leukocyte populations, the surface marker expression of monocytes, and the number of myeloid subpopulations was tracked in participants with ALS during multiple clinical visits. These numbers were compared with levels seen in controls and were also correlated with changes in ALSFRS-R score using multivariate regression analysis. The study was performed for several reasons. First, it has become increasingly clear that ALS has an immunologic component 10, 36 : immune changes have been detected in humans with ALS, and altering the function of specific immune cells can alter disease progression in mouse models. Second, the immune system can alter the immune environment within the CNS, polarizing resident cells to a more destructive phenotype, making it an attractive target for therapeutics. Finally, many previous clinical studies 9, 20, 22, 23, 26, [37] [38] [39] examining differences between participants with ALS and controls have focused on single clinical visits; few have focused on changes over time.
In the peripheral blood of participants with ALS, we found a significant increase in the total number of leukocytes per milliliter of blood; numbers of neutrophils, CD16 + monocytes, CD16 − monocytes, and NK cells also increased. Using a multivariate regression model that accounted for baseline values, time from onset, and sex, we found that changes in total numbers of leukocytes, neutrophils, and CD4 T cells were significantly correlated with disease progression, although whether these cells are playing a pathogenic role, positive or negative, in disease progression remains unclear. These analyses were further extended to nongranulocytic myeloid cell populations. We found few differences between participants with ALS and controls in monocytes, although subpopulations of CD14 − nonmonocytic cells showed small but significant differences. Multivariate regression suggested that CX3CR1 expression in various myeloid populations is correlated with disease progression. We observed a CD14 − CD16 − myeloid cell population that showed transient but acute expansion during disease and likely expressed HLA-DR, CD11c, and CX3CR1. For all these significantly correlated metrics, we observed that participants often had immune changes that were contrary to findings for most of the patients. These discrepancies are likely attributable to inherent immune fluctuation 35 because no obvious common factors were found among these participants.
Our observations are consistent with and expand on previous studies examining the role of the immune system in ALS. Modest increases in neutrophil levels have been previously reported.
9,29,37,40,41 However, we demonstrate herein a significant correlation between increases in neutrophils in the peripheral blood and disease progression. These cells could play a protective and/or destructive role; neutrophil infiltrate is associated with enhanced tissue damage, but studies also indicate that neutrophils contribute to neuronal repair. 
Research Original Investigation
Correlation of Peripheral Immunity With Rapid ALS Progression mean NK cell numbers in blood samples from participants with ALS increased over time. These cells may have an effect on disease progression because they are capable of producing proinflammatory cytokines that can skew the immune system toward a destructive response. 49 More directly, NK cells lyse infected, oncogenic, and apoptotic cells. They also target cells lacking major histocompatibility complex I expression, and motor neurons have recently been shown to lack major histocompatibility complex I expression in ALS. 50 However, NK cells can also have a protective effect in the CNS. In multiple sclerosis, NK cells dampen the immune response in the CNS, 51 and CX3CR1 expression is needed for NK-mediated protection.
52
Conversely, almost all information to date indicates that CD4 T cells are protective during ALS.
25,28,29,53-55 Although we did not observe a significant change in CD4 T cell counts between participants with ALS and healthy controls, we found that decreasing CD4 T-cell levels were correlated with disease progression. This correlation is likely attributable to reduced numbers of regulatory T cells within the CD4 population because regulatory T cells skew the immune system toward a protective response and delay ALS progression in mouse models. 56 Moreover, human studies have found that reduced regulatory T-cell levels are associated with rapid ALS progression. 25 We did not examine CD4
T cells for regulatory function in the present study, but such an examination may form the basis of future investigation. 
Limitations
This study is correlative. Although the data are consistent with previous clinical reports and mouse models of ALS, changes in peripheral immunity may be a consequence rather than a cause of disease. In addition, participants in the study did not provide samples until 6 to 12 months after the initial diagnosis of ALS, meaning that the earliest stages of disease were often not examined in the study. Finally, subpopulations of CD4 T cells were not examined; decreases in ALSFRS-R may correlate with decreases in specific CD4 T-cell subpopulations rather than CD4 T cells as a whole.
Conclusions
In this study, we demonstrate that changes in the number of immune cells, particularly neutrophils and CD4 T cells, are correlated with disease progression. Other cell populations, such as NK cells and a population of CD11b 
